Omega Pharma - Resultaten Q1 2005

SALES FLASH Q1/2005
Turnover grows 28% in first quarter
In the first quarter of 2005 Omega Pharma achieved a turnover of €226.2 million. This is a growth of
27.7% compared to the same period last year. The external growth is 18%1, the internal growth is 9.7%.
The split of the turnover is as follows:
The OTC activities thus represent 70% of the turnover.
The turnover evolution per business unit is as follows:
In million euros Q1/2005 Q1/2004 % evolution
Omega Belgium 45.3 35.9 + 26%
Omega France 42.5 40.9 + 4%
Omega Europe 70.8 36.1 + 96%
Fagron group 23.6 20.3 + 16%
OmegaSoft 6.3 6.1 + 3%
Omega Dental 24.0 25.1 - 4%
Omega Medical 13.7 12.7 + 8%
Total 226.2 177.1 + 28%
􀂒 The growth of Omega Belgium was mainly driven by a substantial increase in the EG-generics and
strong growth of the Star Brands Fat Control, Davitamon and Bergasol and the Key Brands Galenco,
Bodysol and T.Leclerc.
􀂒 The turnover for Omega France rose 4%. Currently, in the framework of the Vitamin O project, an
important reorganisation is being carried out in order to reduce the costs and to increase
profitability.

􀂒 Omega Europe almost doubled in turnover, from €36.1 million in Q1/2004 to €70.8 million in
Q1/2005.
- The turnover in the Netherlands grew 13% to €10.9 million, mainly due to Davitamon and
Parfenac.
- The activities in Germany increased by 47% to €8.5 million due to the growth of almost all
brands.
- The turnover of Omega in Spain increased by 39% to €9.1 million, mainly as a result of internal
growth.
- The OTC activities in the UK increased 59% to €8.5 million. The new organisation structure, set
up after the strong growth in 2003 and 2004, is gradually increasing in effectiveness.
- Activities in Portugal (Chefaro Portugal and Prisfar) continue to grow strongly, this time by 33%
to €4.3 million.
- Activities in Greece decreased 20% to €3.4 million, caused by delayed deliveries.
- For the first time the activities in Italy are managed on an overall basis (Pfizer brands and
Medestea). The quarterly turnover of well over €12 million is promising.
- The same can be said of Scandinavia. They achieved €11.6 million turnover, amongst others
thanks to 15% internal growth in Sweden.
􀂒 The strong growth of Omega Europe, the OTC division with the highest profitability and the highest
synergetic potential, shows that the implementation of the Omega strategy is succesful in different
European countries. This business unit will be the basis for substantial growth of the Omega Pharma
group in the long term.
􀂒 The business-to-business divisions grew 5% to €67.6 million. At OmegaSoft (+ 3%) and Omega
Medical (+ 8%) the emphasis lies on the Vitamin O project. The Fagron group saw its growth
accelerate to 16% due to the European competitive advantage. Omega Dental (- 4%) had a weaker
quarter but it retains its annual prognosis.
Prognoses2
The 2005 consolidation year has started favourably for Omega Pharma.
The European structure set up in 2004 generates competitive advantages and synergetic potential, which
has resulted in an internal growth of 9.7%.
Throughout the entire year of 2005 the Vitamin O project will be implemented; for 2005 this will result
in savings of €25 million. In the first quarter many related structural decisions were made with a quarter
impact of €3 million. It is expected that the EBITDA will have risen by at least 15% in Q1/2005
compared to Q1/2004 and that from the third quarter on profitability will grow faster than turnover.
The results of the first quarter are an important step in achieving the year prognosis, i.e. €950 million in
turnover, €150 million current EBITDA and €3.50 net current profit per share.